Pfizer Wins FDA Approval for IBRANCE, Cutting Breast Cancer Progression Risk 24%

Pfizer received U.S. Food and Drug Administration (FDA) approval for the expanded use of IBRANCE (palbociclib). The approval covers maintenance treatment for adult patients with HR+, HER2+ advanced or metastatic breast cancer following initial therapy.

This decision establishes IBRANCE as the first and only CDK4/6 inhibitor approved for HR+ metastatic breast cancer patients regardless of HER2 status.

Data from the Phase 3 PATINA trial supported the regulatory decision. Adding IBRANCE to standard treatment regimens resulted in a 24% reduction in the risk of disease progression or death.

The approval reinforces the drug's role as a foundational treatment for metastatic breast cancer over the last decade.